Eli Lilly is preparing a large-scale expansion in China, with an investment of $3 billion. According to Reuters and BioSpace, the interest of the Chinese authorities is not only due to commercial prospects. Beijing wants to accelerate access to innovative drugs and localize their production at the same time. Among the proposed measures are simplified market entry procedures, support for clinical trials and partnerships with local companies.
The main focus is on new-generation drugs: these are GLP-1 hormone-based drugs. Originally developed for the treatment of diabetes, they have shown high efficiency in weight loss. This has led to a global surge in demand.
According to clinical studies, Eli Lilly drugs can reduce body weight by an average of 15-16%. In individual cases, the figures can be significantly higher. At the same time, improvement of blood sugar levels is recorded, which makes such drugs in demand in patients with metabolic disorders.
Pfizer and Novo Nordisk are the main competitors
Against this background, competition between major pharmaceutical companies is intensifying. Among the main rivals are Pfizer and Novo Nordisk, which are also actively developing their own lines of drugs for weight control and diabetes.
For pharma operators, China is seen as a key market. Obesity rates are rising in the country and demand for modern therapies is increasing. The authorities are betting on the development of biotechnology and reducing dependence on imported drugs.
Regulators are expected to make decisions on a number of new drugs, including Eli Lilly’s developments, in the near future. Their approval may accelerate the redistribution of forces in the global market and increase competition between players.
